CMTP Research Director Reza Alavi, MD, MHS, MBA with Bonnie Arkus
Baltimore, Nov 2011 - Nearly 200 heart leaders attended the second annual
CMTP Leadership Summit on Cardiovascular Disease last month that brought together leading experts and stakeholders in cardiovascular disease and comparative effectiveness research (CER) to identify the challenges and explore the opportunities to use CER to improve evidence generation and translaton in the realm of cardiovascular disease.
Meeting proceedings were intended to provide input to the Patient Centered Outcomes Research Institute (PCORI) and other CER organizations as they determine how to implement CER principles and methods and translate them into large research portfolios and programs.
Click here to download conference agenda
Representing the patient community, both as a speaker/responder on the discussion panel on diagnostic testing for heart disease, as well as a leader of a breakout sessions on how to engage women patients to take part in clinical trials, was Bonnie Arkus, RN, founder and president of the Women's Heart Foundation.
Ms. Arkus was charged with organizing a 4-member patient panel. Attending the conference with Ms. Arkus were heart patients Lisa R. and Erin P.; contributing members not in attendance were
Dr. Lula L., Marcia D., Marianne D. and Terri B.
Ms. Arkus spoke to the topic of Diagnositc Testing in CVD, moderated by Roger Blumenthal MD of The Johns Hopkins Bloomberg School of Public Health.
Ms. Arkus advocated for cardiovascular leaders to use more widely the Multifunction Cardiogram
as new technology that can more accurately diagnose women's heart disease.
It is a more efficient and effective diagnostic tool for early recognition of ischemic heart disease, she said, with far greater accuracy than stress testing
and without untoward side effect of any kind.
MCG involves no use of radioisotope, X-ray or dyes that confer cancer risk. The MCG can adjudicate whether the cardiac catheterization procedure is indeed necessary, a procedure
that places a patient at risk of hemorrhage, especially in the female population, and even death. A recent study
by Manesh R. Patel, MD, of Duke University, and colleagues revealed overuse of the cardiac catheterization procedure.
Patel said that “every step along the way in determining who gets to the cardiac cath lab needs to be improved.”
MCG is the only noninvasive test to accurately diagnose heart disease in women, and can safely be used in pregnant women, she said.
The conference took place at the Sheraton Inner Harbor Hotel, Baltimore, MD.
Pic1: CMTP Senior Research Director Kathleen Blake, MD, MPH with Priyanka Desai MSPH, CPH
Pic2: Dr. Blake, Bonnie Arkus, Dr. Alazi
Pic1: Dr. Brindis, MD, MPH, and panel: Dr. Bauchner, Dr. Jacques, industry rep Patel, Dr. White
Pic2: Audience members listen intently to the discussion
- Bonnie Arkus, RN, Founder and Exectutive Director, Women’s Heart Foundation
- Kathleen Blake, MD, MPH, Senior Research Director, Center for Medical Technology Policy
- Ralph Brindis, MD, MPH,Clinical Professor of Medicine, University of California – San Francisco; Immediate Past President, American College of Cardiology
- Nancy Davenport-Ennis, Chief Executive Officer, National Patient Advocate Foundation
- Pamela Douglas, MD,Director, CV Imaging Program, Duke Clinical Research Institute; Professor of Medicine in Cardiology and Ursla Geller Professorship for Research in Cardiovascular Diseases, Duke Clinical Research Institute
- David Holmes, MD, President, American College of Cardiology; Professor of Medicine, Mayo Clinic College of Medicine; Consultant, Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic
- Louis Jacques, MD, Director, Coverage and Analysis Group, Centers for Medicare & Medicaid Services
- Michael Lauer, MD, Director of the Division of Cardiovascular Sciences (DCVS), National Heart, Lung, and Blood Institute
- Michael Mack, MD, PhD, President, Society of Thoracic Surgeons
- David Naftel, PhD, MS, Professor of Surgery and Biostatistics, University of Alabama at Birmingham
- Eric Peterson, MD, MPH, Professor of Medicine, Division of Cardiology, Duke University Medical Center, Associate Director, Duke Clinical Research Institute
- Matha Radford, MD, Chief Quality Officer, New York University Langone Medical Center, Professor of Medicine (Cardiology)NYU School of Medicine
- Gilbert Raff, MD, Director, Beaumont Hospital’s Ministrelli Center for Advanced Cardiovascular Imaging, Member, Advanced Cardiovascular Imaging Consortium of Michigan
- Rita Redberg, MD, MSC, Director, Women’s Cardiovascular Services, UCSF Medical Center, Editor in Chief, Archives of Internal Medicine
- Lawrence Sadwin, President, Friends of the World Heart Federation
- Art Sedrakyan, MD, PhD, Director, Comparative Effectiveness Program, Weill Cornell Medical College
- Joe Selby, MD, MPH, Executive Director, Patient-Centered Outcomes Research Institute
- James Tcheng, MD, Professor of Medicine and Professor of Community and Family Medicine, Duke University Medical Center
- Kevin Volpp, MD, PhD, Professor of Medicine and Health Care Management, Director, Center for Health Incentives, Leonard Davis Institute of Health Economics, Director, Penn CMU Roybal P30 Center in Behavioral Economics and Health
- Armin Weinberg, PhD, Chief Executive Officer, Life Beyond Cancer, Clinical Professor, Baylor College of Medicine
- William Weintraub, MD, Director, Division of Cardiovascular Disease, Christiana Care Health Services
- Janet Wright, MD, Senior Vice President for Science and Quality, American College of Cardiology
- Clyde Yancy, MD, Chief, Division of Cardiology, Northwestern University, Feinberg School of Medicine, Magerstadt Professor of Medicine, Northwestern University, Feinberg School of Medicine
The Women's Heart Foundation (WHF), a 501c3 and the only non-governmental organization that implements heart disease prevention projects, is dedicated to prevention of heart disease and improving survival and quality.
The Center for Medical Technology Policy (CMTP) is a private, non-profit organization that provides a neutral forum in which patients, clinicians, payers, manufacturers and researchers can work together to design and implement prospective, real world studies to inform health care decisions. The primary goal of CMTP is to improve the process for generating reliable and credible information about the real world risks, benefits and costs of promising new medical technologies.
- end -